The Commissioning Support Programme through which NICE assessed the cost-effectiveness of medicines being commissioned by NHS England is set to end on 1 June 2019.
NICE, the National Institute for Health and Care Excellence, says:
“The voluntary scheme for branded medicines pricing and access (published in November 2018) means that we no longer need to support the policy development process.”
NICE will have completed all its work for the CSP during May 2019. However, NHS England commissioning will continue:
“NHS England will continue to develop specialised clinical commissioning policies for off-licence and off-label medicines and medicines receiving routine licence extensions which are not appraised by NICE. From the 1 June 2019, NHS England will also continue to develop Commissioning Support Programme topics which haven’t been considered by the clinical priorities advisory group.”